
NeurologyLive® Brain Games: February 15, 2026
Key Takeaways
- A recurring three-question format is used to assess knowledge across a broad neurology curriculum with both clinical and historical framing.
- This week’s focus highlights the regulatory landscape of Duchenne muscular dystrophy by emphasizing FDA-approved drug options.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FDA-Approved Drugs for Duchenne Muscular Dystrophy!
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of the FDA-Approved Drugs for Duchenne Muscular Dystrophy.
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
Which FDA-approved therapy for Duchenne muscular dystrophy is a micro-dystrophin gene transfer delivered via an adeno-associated viral (AAV) vector?
Eteplirsen is FDA-approved for patients with Duchenne muscular dystrophy amenable to skipping which dystrophin exon?
Which FDA-approved exon-skipping therapy targets mutations amenable to exon 53 skipping?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?

















